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Dr Michael E. Jessen (Dallas, Tex). I enjoyed your study, but
several of the observation that you made seemed counterintuitive.The Journal of Thoracic and CaFor example, what is your explanation for why what you call con-
tractility actually was greater in the ischemic zones?
DrChu.That is a very good question.Wewere surprised by that
as well. I think the other surprising thing that we also found was
that mean arterial pressure was actually decreased in the high-cho-
lesterol animals. The improvement in contractility may have some
relationship with the decreased mean arterial pressure and de-
creased afterload, but we are not really sure why that is. It may
be an effect of the drug celecoxib (Celebrex), but without having
a controlled, non–drug-treated group, it would be hard to make
that conclusion.
Dr Jessen. If what you are calling contractility is affected by
afterload, then it is really not contractility by a pure definition.
Did you consider doing anything to measure dimensions in those
2 zones to try to get a better handle on that?
Dr Chu. Unfortunately, we did not; we did not do any echo or
any pressure–volume loop analysis. We are moving into that realm
now, so I hope in future studies we will be able to look at those
things.
Dr Jessen. The other thing was that the contractility was in-
creased, but this was in areas where there was decreased blood
flow. Was that what I took from your talk?
Dr Chu. There was a trend toward decreased blood flow, but it
was not statistically significant.
Dr Jessen. That would be an unusual combination of events as
well. Finally, what is your explanation for the ischemic areas
seeming to have a decreased thrombogenic ratio? That seems
counterintuitive as well.
Dr Chu. That is a great question as well. As you know, throm-
boxane and prostacyclin are partially released by the endothelium
in tissues in the body. It is possible that ischemia affects the
balance of the release of those prostanoids to favor prostacyclin re-
lease, thus decreasing the thrombogenic ratio. Again, the explana-
tion for that is uncertain at this point.
Dr PatrickM.McCarthy (Chicago, Ill). The bottom line ques-
tion is, if your dad was receiving celecoxib and that was the last
available drug that actually works well for his arthritis, how would
you balance these factors?
Dr Chu. Right. That is the million dollar question. However,
this study was not really adequately designed to specifically assess
the safety profile of celecoxib because we did not include a non–
drug-treated group. However, we have done another study that is
currently under review comparing celecoxib use in high-choles-
terol pigs to non–drug-treated high-cholesterol pigs. It does sur-
prise me to have some beneficial effects with regard to reducing
oxidative stress, actually increasing blood flow in the ischemic
territory. I think definitely the safety profile of the drug deserves
further investigation.rdiovascular Surgery c Volume 142, Number 3 681
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